The North America preeclampsia diagnostics market size was estimated at USD 400 million in 2025 and is projected to be worth around USD 532.37 million by 2035, growing at a CAGR of 2.9% from 2026 to 2035. The obese population has increased due to various health conditions, and it is visible in pregnant women. Following this, the need for a suitable diagnostic solution is accelerating the market expansion in healthcare. While the biomarkers' improving status is stimulating the clinicians' performance in preeclampsia predictions.

Asia Pacific Preeclampsia Diagnostics Market Statical Scope

Rising hypertension during pregnancy is common due to the surrounding stress and other existing conditions disturbing the pregnancy period. The mobile solution and POC trend in healthcare is strengthening the accessibility for rural individuals seeking a quick and convenient solution for the preeclampsia condition. The modernized blood test system is pointing towards precision diagnosis for the screening of protein biomarkers.

The improvisation in healthcare infrastructure is introducing new advancements in the market with these remarkable efforts of most of the clinics, centers and hospitals. The modern diagnostics is an essential need for the growing obesity and diabetes conditions. The powerful diagnostic tool participation is a mechanism for the market to move beyond the traditional process.

Asia Pacific Preeclampsia Diagnostics Market Share, By Test Type, 2025 (%)

• Blood Tests – The blood tests segment acquired 61% of the share due to the heavy traffic at the hospitals for the modern preeclampsia diagnostics that ensure accuracy in all terms, mainly for pregnant women. Most of the healthcare providers suggest blood tests as an option to detect any condition before it reaches a severe stage.
• Urine Analysis – The urine analysis segment held 39% of the share due to its painless and natural process, perfect for less resource space and routine check-ups. The new urine-related biomarker tests are a great study-based proof for the clinics to experience with and adapt to the lab settings. This tech-driven approach attracts smart revenue in the segmental market

Asia Pacific Preeclampsia Diagnostics Market Share, By Product, 2025 (%)

• Consumables – The consumables segment acquired 55% of the share with the confident trimming of the reagents as per the new guidelines by FIGO. The complications in the pregnancy have become a common concern due to one of the other existing stressors or conditions. This elevates demand for screening and apt specilaized kits.
• Instruments – The instruments segment held 45% of the share due to the smart and popular trend of POC that serves as a complementary support to the market growth. The use of portable devices and robust automated analysers is a major reason for the strong instrument portfolio.

Asia Pacific Preeclampsia Diagnostics Market Share, By End-user, 2025 (%)

• Hospitals – The hospitals segment secured 52% of the share due to the supportive and modern healthcare infrastructure. Hospitals are a primary part of the healthcare system where researchers are encouraged, and needs are addressed. The one-stop solution of painless modern diagnostic technologies is stimulating growth in the segmental market.
• Specialty Clinics – The specialty clinics segment held 21% of the share due to the great performance of POC test, novel biomarker assays and genetic tests in the clinic settings. These modern technologies have largely covered most of the market's excellence. The non-invasive diagnostic tools are adding value to the segment.
• Diagnostic Centers – The diagnostic centers segment acquired 18% of the share due to the rising scenario of late pregnancy and complications that drive the need for responsive diagnostics for stopping the expansion of preeclampsia. The modern prenatal screening is securing more profit for the segmental market.

Competitive Landscape

The market leaders, such as Sera Prognostics, Metabolomic Diagnostics Ltd., Diabetomics, Inc., PerkinElmer, Inc. and LifeCell Diagnostics, are bolstering the foundation of the market with their respective approaches and investments in the development. The smart investments by Siemens and Roche in the R&D sector are highlighting new transitions in diagnostic tools, such as immunoassay-related tests. While the popular LifeCell focuses on fertility solutions that drive demand for the required technicality to handle the preeclampsia condition with precision and care. The alliances and acquisitions among these leaders have long served the healthcare-based solutions for the remarkable patient outcomes and experience.

Segments Covered in the Report

By Test Type

• Blood Tests
• Urine Analysis

By Product

• Consumables
• Instruments

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others